Lilly Profit Up on Sales of Key Drugs  NEW YORK (Reuters) - Eli Lilly and Co. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=LLY.N target=/stocks/quickinfo/fullquote"&gt;LLY.N&lt;/A&gt; on Thursday  said its third-quarter earnings rose as a drop in sales of its  best selling schizophrenia medication was offset by demand for  drugs to treat depression and impotence.